Condition: Acute Promyelocytic Leukemia (APL) · Acute Promyelocytic Leukaemia · Acute Promyelocytic Leukemia With PML-RARA · Sponsor: Quetzal Therapeutics
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Quetzal Site 1 | Duarte, California, United States | Recruiting |
| Quetzal Site 7 | Los Angeles, California, United States | Recruiting |
| Quetzal Site 5 | Stanford, California, United States | Recruiting |
| Quetzal Site 4 | Buffalo, New York, United States | Recruiting |
| Quetzal Site 2 | The Bronx, New York, United States | Recruiting |
| Quetzal Site 8 | Columbus, Ohio, United States | Recruiting |
| Quetzal Site 12 | Nashville, Tennessee, United States | Recruiting |
| Quetzal Site 6 | Houston, Texas, United States | Recruiting |
| Quetzal Site 3 | Charlottesville, Virginia, United States | Recruiting |
| Quetzal Site 11 | Palma de Mallorca, Balearic Islands, Spain | Recruiting |
| Quetzal Site 10 | Cáceres, Spain | Recruiting |
| Quetzal Site 9 | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07504458